Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Associate Professor Dr Lennard YW Lee


Lennard was appointed to Oxford University in one of the silver lining roles in 2023, from NDM's successes in developing the COVID-19 vacine. He is national lead on the UK's cancer vaccine advance. This is a three pronged UK policy to firstly initiate a global advance of cancer vaccines, secondly to start trials across early/late stage cancers across multiple subtypes, and finally to have 10,000 patients through clinical trials by 2030.

This involves founding and facilitating the NHS Cancer vaccine launchpad, a national system to facilitate enrolment into cancer vaccine trials. His team also maintains the UK Cancer Vaccine bulletin, a monthly newsletter to clinicians in the UK. Through work with UK government officials, he has a role in bridging the clinical community to emergent industrial opportunities to ensure that all involved have optimal experiences of cancer vaccine develompent in the UK.

He is an accomplished Oxford University physician with a successful track record in delivering strategic national projects. Combing academic expertise with effective project management and the strongest background in healthcare, Lennard has made significant contributions in advancing projects for healthcare systems, industrial partners, government and those affected by cancer.


He has received numerous awards for his efforts, including the National ACP McElwain Prize for work during the pandemic, and the IAP’s 21 Outstanding Young Physicians award, given to individuals under the age of 40 who have made outstanding contributions to the field. He has a strong track record of academic achievements, with over 50 publications in the highest impact journals, including the Lancet and JAMA.

Social media

Lennard Lee

DPhil, MA (Cantab), BmBCh (Oxon)

Associate Professor- cancer vaccines | University of Oxford

  • NHSE national clinical advisor on early diagnosis, and the NHS Cancer Vaccine Launchpad
  • Senior clinical advisor, Office for Life Sciences and national cancer vaccine lead
  • Honorary consultant in Medical Oncology, Oxford University Hospitals NHS Foundation Trust
  • Scientific Lead, Independent SAGE


Lennard's modus operandi is to empower those involved in cancer care, science and research. He is working to lay the groundwork to set the United Kingdom to become a world leader in research for cancer vaccines by 2030. This advance will be achieved by following a similar path laid by Oxford teams during the coronavirus vaccine.

Through openness, acting with the highest level of integrity and humility, the aspiration is that large groups of people could align around strategic projects like an advance of vaccines for cancer, building momentum and ultimately lay the path for project successes. Lennard is dedicated to utilise these approaches to partner and drive innovation, accelerate scientific developments and ultimately deliver real world results for those affected by cancer.

His work and research have been covered by the BBC, ITV, Daily Mail, Tortoise Media, and international news outlets. He is an excellent communicator, as illustrated in his role in IndieSAGE. He is incredibly positive and enthusiastic in forming bridges between academics, industry, patients, government and health system.

Lennard’s has several notable achievements, including as founder of the UK COVID Cancer Program, a unique population-scale programme that utilised data to safeguard cancer patients globally during the pandemic. Furthermore, within the UK Moonshot, he delivered the research and managed the successful scale-up of lateral flow coronavirus diagnostics across our nations. In his NHS role, breaking new records, he successfully embedded the NHS-Galleri trial into 70 hospitals, as senior operations lead. This assessed a new blood test for 50 types of cancer and randomised 140,000 patients in just 10.2 months. For immunocompromised patient groups, he co-founded the impactful Forgotten500k campaign.

Finally, advacing our global leadership in vaccine technology, he helped realise a new UK partnership with a leading cancer vaccine company. This transformed domestic Life Sciences capabilities, and established access to cancer vaccine trials for 10,000 patients across multiple tumour types and stages.